Figure 7.

The effect of nab-paclitaxel and bevacizumab combination therapy on tumor growth and metastasis in HCC1806-RR model in vivo. (A) HCC1806-RR tumors were implanted into the MFP and monitored two to three times per week. Each line represents the mean daily tumor volume ± SE. The black and red arrows indicate the beginning of treatment and recurrence after nab-paclitaxel treatment, respectively. (B) ILN, (C) CLN, and (D) lungs were assessed for metastatic burden. Each dot represents the metastatic burden for individual mice in each group as measured by luciferase activity normalized per mg of total protein. The results are expressed as mean RLU/mg protein. The black bar indicates the mean metastatic burden for each group (n = 10). Statistically significant differences in metastatic burden were identified by a Wilcoxon ranked sums test (*P < .05, **P < 0).